Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Claudel, T; Sturm, E; Kuipers, F; Staels, B.
The farnesoid X receptor: a novel drug target?
Expert Opin Investig Drugs. 2004; 13(9):1135-1148
Doi: 10.1517/13543784.13.9.1135
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Claudel Thierry
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Bile acids are end products of cholesterol metabolism. They are exclusively synthesised by the liver and subsequently secreted via the bile duct into the intestine to facilitate the absorption of dietary fat and fat-soluble vitamins. Nuclear receptors are ligand-activated transcription factors. The farnesoid X receptor (FXR) has recently been identified as a bile acid-activated nuclear receptor. FXR controls bile-acid synthesis, conjugation and transport, as well as lipid metabolism. Recent advances in FXR biology demonstrate that FXR may represent a valuable target for the identification of novel drugs to treat dyslipidaemia and cholestasis. However, for therapeutic purposes the development of selective FXR modulators, which only activate or inhibit specific FXR target genes and as such induce specific responses, will be required.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Antilipemic Agents - pharmacology
- Benzene Derivatives - chemistry
- Chenodeoxycholic Acid - analogs and derivatives
- Cholestasis - drug therapy
- DNA-Binding Proteins - agonists
- Humans - agonists
- Hyperlipidemias - drug therapy
- Molecular Structure - drug therapy
- Octanoic Acids - chemistry
- Phenyl Ethers - chemistry
- Receptors, Cytoplasmic and Nuclear - chemistry
- Transcription Factors - agonists
- Find related publications in this database (Keywords)
- bile acid
- cholestasis
- FXR
- lipid metabolism
- nuclear receptor